Physician profile
Robert E Percy
NPI 1285686816
$7,562.77
in general payments reported to CMS, 2019-2025
34 companies · $1,649 in 2025
The $1,649 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $929 · 2020: $830 · 2021: $980 · 2022: $1,380 · 2023: $775 · 2024: $1,019 · 2025: $1,649.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,443.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,442.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,291.95 | 2019-2025 | Trelegy Ellipta, Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $728.86 | 2019-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Actelion Pharmaceuticals US, INC. | $675.42 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Electromed, INC. | $577.10 | 2019-2025 | Smartvest |
| Astrazeneca Pharmaceuticals LP | $542.45 | 2019-2025 | Tezspire, Breztri, Fasenra |
| Intuitive Surgical, INC. | $263.89 | 2022 | |
| Genzyme Corporation | $243.96 | 2019-2025 | |
| United Therapeutics Corporation | $237.60 | 2020-2025 | Tyvaso, Tyvaso, Remodulin |
| Regeneron Healthcare Solutions, INC. | $221.78 | 2019-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $188.89 | 2019-2025 | Zerbaxa, Recarbrio, Dificid |
| Insmed, INC. | $180.23 | 2023-2025 | Arikayce |
| Jazz Pharmaceuticals INC. | $166.37 | 2021-2025 | |
| Grifols USA, LLC | $141.17 | 2021-2022 | |
| Philips North America LLC | $135.70 | 2019-2020 | |
| Gilead Sciences, INC. | $85.94 | 2019-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $85.50 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $83.23 | 2019-2022 | |
| Genentech USA, INC. | $81.62 | 2019-2020 | |
| Amgen INC. | $79.92 | 2025 | Tezspire |
| Pfizer INC. | $78.91 | 2020-2022 | |
| Axsome Therapeutics, INC. | $74.96 | 2024-2025 | Sunosi |
| Viatris Specialty LLC | $72.94 | 2025 | Yupelri |
| Chiesi USA, INC. | $42.34 | 2021-2022 | |
| Inogen, INC. | $40.36 | 2022-2024 | |
| Advanced Respiratory, INC | $37.88 | 2021 | |
| Mylan Specialty L.P. | $31.69 | 2019-2021 | |
| Avadel Cns Pharmaceuticals, LLC | $29.45 | 2025 | Lumryz |
| Circassia INC. | $25.06 | 2019 | |
| Vifor Pharma, INC. | $23.97 | 2025 | Zemaira |
| Verona Pharma, INC. | $22.02 | 2025 | Ohtuvayre |
| Harmony Biosciences LLC | $20.79 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.07 | 2025 | Glassia |
| Bayer Healthcare Pharmaceuticals INC. | $17.47 | 2023 | |
| Olympus America INC. | $15.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Percy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.